View Older Stories View More Recent Stories
-
EMA panel recommends approval of Moderna's new COVID vaccine mNEXSPIKE
-
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
-
FDA may add black box warning to Covid-19 vaccines, CNN says
-
Jefferies Starts Moderna (MRNA) at Hold
-
FDA probe of alleged deaths tied to Covid shots includes adults
-
FDA Probe Of Alleged Deaths Tied To Covid Shots Includes Adults
-
Moderna (MRNA) on watch following comments at Piper
-
Piper Sandler on Moderna (MRNA): 'Project Revenue Growth to Resume'
-
Shares of vaccine makers drop after FDA memo flags reports of child deaths
-
Moderna (MRNA) Sentiment Can Improve with Prudent Near-Term Financial Execution - UBS
-
Needham Reiterates Hold Rating on Moderna (MRNA)
-
Moderna (MRNA) PT Raised to $18 at Leerink Partners
-
Moderna (MRNA) PT Lowered to $25 at RBC Capital
-
Moderna secures $1.5 billion credit facility from Ares Management
-
Moderna targets 10% revenue growth in 2026 with vaccine expansion plans
-
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
-
Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
-
Moderna to move drug manufacturing to Massachusetts facility
-
Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities
-
Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
-
Bernstein Reiterates Market Perform Rating on Moderna (MRNA)
-
Stock market today: S&P 500 falls as job cuts stoke economic fears, tech stutters
-
Moderna revenue falls 45%, but still tops estimates
-
Moderna (MRNA) Tops Q3 EPS by $1.54
-
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates
-
Moderna (MRNA) call put ratio 3.9 calls to 1 put into quarter results
-
Moderna doses first patient in multiple myeloma T-cell engager trial
-
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
-
Moderna (MRNA) call put ratio 4.2 calls to 1 put as share price up 17.4%
-
Moderna (MRNA) Trades Higher on Chatter
-
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
-
Moderna to Host Investor Event - Analyst Day
-
Moderna (MRNA) PT Lowered to $40 at UBS
-
Moderna (MRNA) PT Lowered to $12 at Leerink Partners
-
After-hours movers: Tesla, IBM, Molina, Southwest Airlines, and more
-
Moderna CMV vaccine fails phase 3 trial, development discontinued
-
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
-
Needham Reiterates Hold Rating on Moderna (MRNA)
-
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
-
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
-
Moderna reports early cancer therapy data at medical conference
-
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress
-
Acting CDC head Jim O’neill: I call on vaccine manufacturers to develop safe monovalent vaccines to replace the combined MMR - X post
-
Moderna (MRNA) call put ratio 9.5 calls to 1 put with a focus on October 3 weekly and October 10 weekly 10 calls
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
Rfk Jr. Weighs Expansion Of Vaccine Injury Program: Adviser - Bloomberg
-
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
-
Brookline: 'We currently estimate that 2025 Moderna COVID-19 vaccine sales will include 10.9 million doses in the US'
-
Moderna vaccine shows strong immune response against LP.8.1 variant
-
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
